Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.52 |
| ▸ | NOS1 | P29475 | 10/20 | 0.50 |
| ▸ | NOS2 | P35228 | 4/20 | 0.48 |
| ▸ | NOS3 | P29474 | 2/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22511690 | 0.82 | NOS1 (0.65) | BACE1NOS1NOS2NOS3NCF1 | |
| SCHEMBL7046423 | 0.80 | NOS1 (0.56) | BACE1NOS1NOS2NOS3NCF1 | |
| SCHEMBL22521588 | 0.76 | NOS1 (0.50) | BACE1NOS1NOS2 | |
| SCHEMBL24254206 | 0.76 | NOS1 (0.50) | BACE1NOS1NOS2NOS3 | |
| SCHEMBL20475572 | 0.74 | TLR8 (0.38) | NOS1NOS2NOS3 | |
| SCHEMBL20475571 | 0.74 | PRMT5 (0.38) | BACE1NOS1 | |
| SCHEMBL20721560 | 0.74 | TLR8 (0.40) | BACE1NOS1NOS3 | |
| SCHEMBL20475558 | 0.73 | NCF1 (0.50) | NOS1NOS2NOS3NCF1 | |
| SCHEMBL22381237 | 0.73 | NOS1 (0.49) | NOS1NOS2NOS3 | |
| SCHEMBL19405238 | 0.73 | NOS1 (0.48) | BACE1NOS1NOS2NOS3NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218732-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2022-07-14 | — | — | US | claimed |
| US-20220152072-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2022-05-19 | — | — | US | claimed |
| US-20220153747-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2022-05-19 | — | — | US | claimed |
| EP-3952874-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 | Prelude Therapeutics, Incorporated (US) | 2022-02-16 | — | — | EP | claimed |
| EP-3939986-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | Prelude Therapeutics, Incorporated (US) | 2022-01-19 | — | — | EP | claimed |
| WO-2020206308-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2020-10-08 | — | — | WO | claimed |
| WO-2020206289-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2020-10-08 | — | — | WO | claimed |
| CN-111527099-A | Selective inhibitors of protein arginine methyltransferase 5(PRMT5) | 普莱鲁德疗法有限公司 | 2020-08-11 | — | — | CN | claimed |
| EP-3665179-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | Prelude Therapeutics, Incorporated (US) | 2020-06-17 | — | — | EP | claimed |
| WO-2019032859-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2019-02-14 | — | — | WO | claimed |
| WO-2018152548-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2018-08-23 | — | — | WO | claimed |
| CN-111527099-B | Selective inhibitors of protein arginine methyltransferase 5 (PRMT 5) | 普莱鲁德疗法有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20220218732-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2022-07-14 | — | — | US | disclosed |
| US-20220152072-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2022-05-19 | — | — | US | disclosed |
| US-20220153747-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2022-05-19 | — | — | US | disclosed |
| US-20190048014-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2019-02-14 | — | — | US | disclosed |
| WO-2019032859-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2019-02-14 | — | — | WO | disclosed |
| WO-2018160824-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2018-09-07 | — | — | WO | disclosed |
| WO-2018160855-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2018-09-07 | — | — | WO | disclosed |
| WO-2018152548-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2018-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218732-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRMT5, PRMT6, PRMT1 | BACE1 1978/4885NOS1 1111/4885NOS2 982/4885 |
| US-20220152072-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | BACE1 1636/4885NOS1 1244/4885NOS2 1331/4885 |
| US-20220153747-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | BACE1 1102/4885NOS1 424/4885NOS2 597/4885 |
| US-20190048014-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | BACE1 1685/4885NOS1 1003/4885NOS2 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.